Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 42
Filter
1.
Clin Dermatol ; 41(4): 476-480, 2023.
Article in English | MEDLINE | ID: mdl-37574152

ABSTRACT

Eyelid dermatitis may present with a variety of clinical findings including erythema, pruritus, and edema, and it has a wide differential. Allergic contact dermatitis due to allergen sources in personal care products, cosmetics, and fragrances is a leading cause of eyelid dermatitis and may be challenging to diagnose by clinical examination alone. Expanded patch testing, in addition to careful inspection of the surrounding skin for additional areas of involvement and clinical clues, remains an important tool in differentiating allergic contact dermatitis from other relevant etiologies of eyelid dermatitis including irritant contact dermatitis, atopic dermatitis, seborrheic dermatitis, and rosacea. We present a practical approach to the management of eyelid dermatitis including the use of a topical anti-inflammatory for long-term control of eyelid findings. Further diagnostic workup may be warranted in patients with refractory eyelid dermatitis.


Subject(s)
Blepharitis , Cosmetics , Dermatitis, Allergic Contact , Dermatitis, Atopic , Humans , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/etiology , Dermatitis, Atopic/diagnosis , Eyelids , Allergens/adverse effects , Cosmetics/adverse effects , Patch Tests/adverse effects , Blepharitis/diagnosis , Blepharitis/etiology , Blepharitis/therapy
5.
Am J Clin Dermatol ; 23(1): 61-67, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34855151

ABSTRACT

Dupilumab facial redness (DFR), or the development of an eczematous rash of the face and neck with dupilumab use, has been observed in recent case reports. It is estimated to impact between 4 and 43.8% of dupilumab users, including children and adults. Aside from reviewing the pathogenesis and clinical presentation, we present potential diagnostic steps (such as skin scraping, serologies, biopsy, and patch testing) and management options for DFR ranging from allergen avoidance to dupilumab interruption. It is hoped that this article will serve as a means for clinicians to familiarize themselves with DFR regarding the differential diagnosis, diagnostic tools, and treatment options associated with this phenomenon.


Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Erythema/chemically induced , Facial Dermatoses/chemically induced , Administration, Topical , Anti-Bacterial Agents/therapeutic use , Antifungal Agents/therapeutic use , Calcineurin Inhibitors/therapeutic use , Diagnosis, Differential , Drug Eruptions/diagnosis , Erythema/therapy , Facial Dermatoses/therapy , Glucocorticoids/therapeutic use , Humans , Skin Tests
6.
Clin Dermatol ; 39(5): 757-761, 2021.
Article in English | MEDLINE | ID: mdl-34785003

ABSTRACT

Water has numerous functions necessary for survival including cellular homeostasis, solvent properties for dissolving ions and solutes, thermoregulation, and transport of waste and nutrients. Despite the established beneficial role of water in skin physiology, the optimal methods for skin hydration and requirements for daily water consumption remain elusive. This review summarizes the cellular and molecular biology of skin hydration, the debate and current recommendations of daily water requirements, and the latest research on interventions to improve skin hydration by both internal and external means of water exposure. We also explore the chemical properties of water, such as the concept of water "hardness" and environmental pollutants, and their impact on skin physiology.


Subject(s)
Skin Physiological Phenomena , Water , Humans , Skin
7.
Clin Dermatol ; 39(5): 762-771, 2021.
Article in English | MEDLINE | ID: mdl-34785004

ABSTRACT

Cigarette and electronic cigarette use are significant public health concerns across the United States. Tobacco use remains the single most preventable cause of morbidity and mortality in the world. Electronic cigarettes initially emerged as a better alternative to conventional cigarettes and for promoting smoking cessation; however, current evidence reveals similar deleterious health implications caused by both products on almost all organ systems, including the skin. Recognition of the cutaneous manifestations associated with cigarette and electronic cigarette use is essential for dermatologists in current clinical practice. Dermatologists play a vital role in educating and counseling patients on smoking cessation. We specifically highlight the cutaneous consequences of conventional cigarette smoking and electronic cigarettes on dermatologic disease.


Subject(s)
Electronic Nicotine Delivery Systems , Tobacco Products , Vaping , Humans , Nicotiana , Tobacco Use , United States/epidemiology , Vaping/adverse effects
16.
Clin Dermatol ; 38(5): 580-583, 2020.
Article in English | MEDLINE | ID: mdl-33280807

ABSTRACT

Drug reaction with eosinophilia and systemic clinical manifestations (DRESS syndrome) is a potentially fatal drug reaction that is hallmarked by a hypercytokinemic state that results in organ dysfunction. For this reason, plasmapheresis and therapeutic plasma exchange are being increasingly utilized in DRESS syndrome refractory to systemic corticosteroids to remove the pathogenic cytokines that cause end-organ damage. This contribution proposes a novel approach to DRESS syndrome complicated by acute kidney injury. Specifically, the authors argue that patients with DRESS syndrome complicated by acute kidney injury may benefit from utilization of specific forms of renal replacement therapy that also provide plasmapheresis. This is relevant acute kidney injury that develops in more than one-third of cases of DRESS syndrome with at least 10% of cases progressing to acute renal failure requiring renal replacement therapy. Renal replacement therapy can include intermittent hemodialysis or continuous renal replacement therapy.


Subject(s)
Acute Kidney Injury/etiology , Acute Kidney Injury/therapy , Drug Hypersensitivity Syndrome/etiology , Drug Hypersensitivity Syndrome/therapy , Drug-Related Side Effects and Adverse Reactions/etiology , Drug-Related Side Effects and Adverse Reactions/therapy , Eosinophilia/etiology , Eosinophilia/therapy , Renal Replacement Therapy/methods , Humans , Plasmapheresis/methods , Renal Dialysis
17.
Int J Womens Dermatol ; 6(2): 94-96, 2020 Mar.
Article in English | MEDLINE | ID: mdl-32258339

ABSTRACT

BACKGROUND: In response to the evolving measles epidemic in the United States, the Centers for Disease Control and Prevention recommended that some adults be revaccinated against measles because they may have inadequate immunity against the virus. Patients receiving biologic medications for psoriasis face a clinical dilemma because they may be at an increased risk of developing severe measles; however, vaccination with the measles-mumps-rubella (MMR) vaccine is not recommended for those on biologic therapy according to the American Academy of Dermatology-National Psoriasis Foundation guidelines. OBJECTIVES: This study aimed to review available research on the safety and efficacy of live-attenuated vaccines in individuals receiving biologic therapy for psoriasis and to discuss our approach to vaccinating individuals on biologic agents for psoriasis with the MMR vaccine. METHODS: A review of the literature was performed via PubMed search. Our institution's anecdotal experiences are also discussed. RESULTS: Data, although limited, are available suggesting that live-attenuated vaccines may be safe for individuals on tumor necrosis factor-alpha inhibitors for psoriasis. Inadequate data are available for patients receiving other biologic medications. CONCLUSION: Providers should engage in shared decision-making to determine whether patients on tumor necrosis factor-alpha inhibitors for psoriasis should receive the MMR vaccine without an interruption in biologic therapy.

18.
J Am Acad Dermatol ; 83(1): 46-52, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32179082

ABSTRACT

BACKGROUND: Bullous pemphigoid (BP) is an autoimmune blistering disorder occurring mostly in the elderly that lacks adequate treatments. OBJECTIVE: To describe our experience using dupilumab in a series of patients with BP. METHODS: This is a case series of patients from 5 academic centers receiving dupilumab for BP. Patients were eligible if they had a clinical diagnosis of BP confirmed by lesional skin biopsy evaluated by one of more of the following: hematoxylin and eosin staining, direct immunofluorescence, or enzyme-linked immunosorbent assay for BP180 or BP230, or both. RESULTS: We identified 13 patients. Patients were an average age of 76.8 years, and the average duration of BP before dupilumab initiation was 28.8 months (range, 1-60 months). Disease clearance or satisfactory response was achieved in 92.3% (12 of 13) of the patients. Satisfactory response was defined as clinician documentation of disease improvement and patient desire to stay on the medication without documentation of disease clearance. Total clearance of the BP was achieved in 53.8% (7of 13) of patients No adverse events were reported. LIMITATIONS: Include small sample size, lack of a control group, lack of a standardized assessment tool, and lack of standardized safety monitoring. CONCLUSION: Dupilumab may be an additional treatment for BP, leading to disease clearance or satisfactory response in 92.3% of patients, including in those in whom previous conventional therapy had failed.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Dermatologic Agents/therapeutic use , Interleukin-4 Receptor alpha Subunit/therapeutic use , Pemphigoid, Bullous/drug therapy , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Pemphigoid, Bullous/diagnosis , Treatment Outcome
19.
Acad Med ; 95(2): 215, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31990727
SELECTION OF CITATIONS
SEARCH DETAIL
...